Have a personal or library account? Click to login
Multi-institutional study of ‘Sandwich treatment’ for motor area large brain metastases (LBM) with diameter over 3 cm Cover

Multi-institutional study of ‘Sandwich treatment’ for motor area large brain metastases (LBM) with diameter over 3 cm

Open Access
|Jan 2024

References

  1. Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro Oncol 20217; 19: 1511–21. doi: <a href="https://doi.org/10.1093/neuonc/nox077" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/neuonc/nox077</a>
  2. Graber JJ, Cobbs CS, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines on the use of stereotactic radiosurgery in the treatment of adults with metastatic brain tumors. Neurosurgery 2019; 84: E168–E170. doi: <a href="https://doi.org/10.1093/neuros/nyy543" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/neuros/nyy543</a>
  3. Han JH, Kim DG, Chung HT, Paek SH, Park CK, Jung HW. Radiosurgery for large brain metastases. Int J Radiat Oncol Biol Phys 2012; 83: 113–20. doi: <a href="https://doi.org/10.1016/j.ijrobp.2011.06.1965" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2011.06.1965</a>
  4. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, et al. Updates in the management of brain metastases 2016; Neuro Oncol 2016; 18: 1043–65. doi: <a href="https://doi.org/10.1093/neuonc/now127" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/neuonc/now127</a>
  5. Devoid HM, McTyre ER, Page BR, Metheny-Barlow L, Ruiz J, Chan MD. Recent advances in radiosurgical management of brain metastases. Front Biosci 2016; 8: 203–14. doi: <a href="https://doi.org/10.2741/s458" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2741/s458</a>
  6. Milano MT, Chiang VLS, Soltys SG, Wang TJC, Lo SS, Brackett, et al. Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro Oncol 2020; 22: 1728–41. doi: <a href="https://doi.org/10.1093/neuonc/noaa192" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/neuonc/noaa192</a>
  7. Hasegawa T, Kato T, Yamamoto T, Iizuka H, Nishikawa T, Ito H, et al. Multisession gamma knife surgery for large brain metastases. J Neurooncol 2017; 131: 517–24. doi: <a href="https://doi.org/10.1007/s11060-016-2317-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-016-2317-4</a>
  8. Dohm AE, Hughes R, Wheless W, Lecompte M, Lanier C, Ruiz J. Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases. J Neurooncol 2018; 140: 749–56. doi: <a href="https://doi.org/10.1007/s11060-018-03008-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-018-03008-8</a>
  9. Yomo S, Hayashi M, Nicholson C. A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors. J Neurooncol 2012; 109: 159–65. doi: <a href="https://doi.org/10.1007/s11060-012-0882-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-012-0882-8</a>
  10. Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, et al. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg 2018; 129: 366–82. doi: <a href="https://doi.org/10.3171/2017.3.JNS162532" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3171/2017.3.JNS162532</a>
  11. Serizawa T, Higuchi Y, Yamamoto M, Matsunaga S, Nagano O, Sato Y, et al. Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases: A retrospective multi-institutional study. J Neurosurg 2018; 131: 227–37. doi: <a href="https://doi.org/10.3171/2018.4.JNS172596" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3171/2018.4.JNS172596</a>
  12. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 2022; 40: 492–516. doi: <a href="https://doi.org/10.1200/JCO.21.02314" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.21.02314</a>
  13. Lehrer EJ, Peterson JL, Zaorsky NG, Brown PD, Sahgal A, Chiang VL, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: An international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys 2019; 103: 618–30. doi: <a href="https://doi.org/10.1016/j.ijrobp.2018.10.038" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2018.10.038</a>
  14. Pintea B, Baumert B, Kinfe TM, Gousias K, Parpaley Y, Boström JP. Early motor function after local treatment of brain metastases in the motor cortex region with stereotactic radiotherapy/radiosurgery or microsurgical resection: A retrospective study of two consecutive cohorts. Radiat Oncol 2017; 12: 177. doi: <a href="https://doi.org/10.1186/s13014-017-0917-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13014-017-0917-6</a>
  15. Loganadane G, Dhermain F, Louvel G, Kauv P, Deutsch E, Le Péchoux C, et al. Brain radiation necrosis: Current management with a focus on non-small cell lung cancer patients. Front Oncol 2018; 8: 336. doi: <a href="https://doi.org/10.3389/fonc.2018.00336" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fonc.2018.00336</a>
  16. Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA, et al. Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 2016; 96: 1060–9. doi: <a href="https://doi.org/10.1016/j.ijrobp.2016.08.039" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2016.08.039</a>
  17. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 45–68. doi: <a href="https://doi.org/10.1007/s11060-009-0073-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-009-0073-4</a>
  18. Desai B, Rassam D, Ezeh P, et al. Phase III trial of PF-06439535 or bevacizumab-eu plus paclitaxel/carboplatin in NSCLC. J Thorac Oncol 2015; 10: S665.
  19. Tamura R, Tanaka T, Miyake K, Yoshida K, Sasaki H. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol 2017; 34: 62–77. doi: <a href="https://doi.org/10.1007/s10014-017-0284-x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10014-017-0284-x</a>
  20. Lubelski D, Abdullah KG, Weil RJ, Marko NF. Bevacizumab for radiation necrosis following treatment of high grade glioma: A systematic review of the literature. J Neurooncol 2013; 115: 317–22. doi: <a href="https://doi.org/10.1007/s11060-013-1233-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-013-1233-0</a>
  21. Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: A systematic review of the literature. J Clin Med Res 2017; 9: 273–80. doi: <a href="https://doi.org/10.14740/jocmr2936e" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.14740/jocmr2936e</a>
  22. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series. Int J Neurosci 2016; 126: 1002–6. doi: <a href="https://doi.org/10.3109/00207454.2015.1092443" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/00207454.2015.1092443</a>
  23. Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013; 74: 136–41. doi: <a href="https://doi.org/10.1055/s-0033-1338262" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1055/s-0033-1338262</a>
  24. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol 2015; 16: e270–e8. doi: <a href="https://doi.org/10.1016/S1470-2045(15)70057-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(15)70057-4</a>
  25. Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD. T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 2010, 66: 486–91. doi: <a href="https://doi.org/10.1227/01.NEU.0000360391.35749.A5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1227/01.NEU.0000360391.35749.A5</a>
  26. Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: Visual assessment versus quantitative assessment. PLoS One 2015; 10: e0132515. doi: <a href="https://doi.org/10.1371/journal.pone.0132515" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0132515</a>
  27. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 2008; 40: 665–71. doi: <a href="https://doi.org/10.2340/16501977-0235" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2340/16501977-0235</a>
  28. Hankemeier A, Rollnik JD. The Early Functional Abilities (EFA) scale to assess neurological and neurosurgical early rehabilitation patients. BMC Neurol 2015; 15: 207. doi: <a href="https://doi.org/10.1186/s12883-015-0469-z" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s12883-015-0469-z</a>
  29. Yomo S, Hayashi M. A minimally invasive treatment option for large metastatic brain tumors: Long-term results of two-session Gamma Knife stereotactic radiosurgery. Radiat Oncol 2014; 9: 132. doi: <a href="https://doi.org/10.1186/1748-717X-9-132" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1748-717X-9-132</a>
  30. Damron EP, Dono A, Chafi H, Martir M, Yu TK, Khwaja S, et al. Metastatic neoplasm volume kinetics following 2-stage stereotactic radiosurgery. World Neurosurg 2022; 161: e210–e9. doi: <a href="https://doi.org/10.1016/j.wneu.2022.01.109" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.wneu.2022.01.109</a>
  31. Hori Y, Muhsen B, Joshi K, Wei W, Borghei-Razavi H, Chao S et al. The efficacy and safety of two-staged stereotactic radiosurgery for large posterior fossa metastases: post-treatment volumetric changes in tumor size, peri-tumoral edema, and fourth ventricle. Neuro Oncol 2020; 22 Suppl2: ii181. doi: <a href="https://doi.org/10.1093/neuonc/noaa215.756" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/neuonc/noaa215.756</a>
  32. Ito D, Aoyagi K, Nagano O, Serizawa T, Iwadate Y, Higuchi Y. Comparison of two-stage Gamma Knife radiosurgery outcomes for large brain metastases among primary cancers. J Neurooncol 2020; 147: 237–46. doi: <a href="https://doi.org/10.1007/s11060-020-03421-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11060-020-03421-y</a>
  33. Cho A, Medvedeva K, Kranawetter B, Untersteiner H, Hirschmann D, Lepilina O, et al. How to dose-stage large or high-risk brain metastases: an alternative two-fraction radiosurgical treatment approach. J Neurosurg 2022; 137: 1666–75. doi: <a href="https://doi.org/10.3171/2022.2.JNS212440" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3171/2022.2.JNS212440</a>
  34. Li J, He J, Cai L, Lai M, Hu Q, Ren C, et al. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts. Ann Palliat Med 2021; 10: 2018–26. doi: <a href="https://doi.org/10.21037/apm-20-2417" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/apm-20-2417</a>
  35. Erpolat OP, Demircan NV, Sarıbas GS, Kuzucu P, Senturk E, Elmas C, et al. A comparison of Ramipril and Bevacizumab to mitigate radiation-induced brain necrosis: An experimental study. World Neurosurg 2020; 144: e210–e20. doi: <a href="https://doi.org/10.1016/j.wneu.2020.08.081" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.wneu.2020.08.081</a>
  36. Ai B, Zhang L, Huang D, Chen J, Liu Z, Hu X, et al. Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. Thorac Cancer 2020; 11: 3641–4. doi: <a href="https://doi.org/10.1111/1759-7714.13687" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/1759-7714.13687</a>
DOI: https://doi.org/10.2478/raon-2024-0002 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 145 - 152
Submitted on: Jul 3, 2023
Accepted on: Sep 23, 2023
Published on: Jan 6, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Zheng Wang, Haining Chen, Qun Chen, Yucun Zhu, Min Li, Jia Zhou, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.